Abstract No. 429 A case control study of percutaneous sclerotherapy versus transcatheter hepatic arterial embolization for treatment of large-volume hepatic hemangioma

Abstract

To evaluate the clinical efficacy of percutaneous sclerotherapy and transcatheter hepatic artery embolization in the treatment of large volume hepatic hemangioma. Twenty-two patiens with large-volume hepatic hemangioma (diameter larger than 5 cm) were randomly divided into two groups between Jan 2015 and Aug 2017 at one single institution. Eleven cases were undergone percutaneous injection of bleomycin sclerotherapy under CT-guidance (sclerotherapy group), 11 patients were performed by DSA-guided bleomycin lipiodol emulsion transcatheter hepatic artery embolization (embolization group). The procedure time, hospital cost, postoperative outcomes, complications and QOL scales were reviewed and analyzed. The mean procedure time (15.6+6.4) min in sclerotherapy group was shorter than that in the embolization group (51.5+7.2) min. The liver dysfunction rate of sclerotherapy group (27.3%, 3/11) was much lower than that in embolization group (90.9%, 10/11). The mean hospitalization and cost of sclerotherapy group were significantly less than that of embolization group, p0.05. At 6 months follow-up post procedure, the effective rate (CR+PR) of sclerotherapy group and embolization group were (81.8%, 9/11), (92.3%, 10/11), respectively, p>0.05. Both approaches (sclerotherapy, embolization) in the treatment of large-volume hepatic hemangioma are effective and safe. Sclertotherapy is more simple, cost-effective method in the treatment of hepatic hemangioma.